319 related articles for article (PubMed ID: 27888721)
1. Discovery of resveratrol derivatives as novel LSD1 inhibitors: Design, synthesis and their biological evaluation.
Duan YC; Guan YY; Zhai XY; Ding LN; Qin WP; Shen DD; Liu XQ; Sun XD; Zheng YC; Liu HM
Eur J Med Chem; 2017 Jan; 126():246-258. PubMed ID: 27888721
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy.
Duan Y; Qin W; Suo F; Zhai X; Guan Y; Wang X; Zheng Y; Liu H
Bioorg Med Chem; 2018 Dec; 26(23-24):6000-6014. PubMed ID: 30448189
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological activity of 3-oxoamino-benzenesulfonamides as selective and reversible LSD1 inhibitors.
Xi J; Xu S; Wu L; Ma T; Liu R; Liu YC; Deng D; Gu Y; Zhou J; Lan F; Zha X
Bioorg Chem; 2017 Jun; 72():182-189. PubMed ID: 28460360
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY
Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602
[TBL] [Abstract][Full Text] [Related]
5. Identification of SNAIL1 Peptide-Based Irreversible Lysine-Specific Demethylase 1-Selective Inactivators.
Itoh Y; Aihara K; Mellini P; Tojo T; Ota Y; Tsumoto H; Solomon VR; Zhan P; Suzuki M; Ogasawara D; Shigenaga A; Inokuma T; Nakagawa H; Miyata N; Mizukami T; Otaka A; Suzuki T
J Med Chem; 2016 Feb; 59(4):1531-44. PubMed ID: 26700437
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
Duan YC; Jin LF; Ren HM; Zhang SJ; Liu YJ; Xu YT; He ZH; Song Y; Yuan H; Chen SH; Guan YY
Eur J Med Chem; 2021 Aug; 220():113453. PubMed ID: 33957387
[TBL] [Abstract][Full Text] [Related]
7. Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity.
Schmitt ML; Hauser AT; Carlino L; Pippel M; Schulz-Fincke J; Metzger E; Willmann D; Yiu T; Barton M; Schüle R; Sippl W; Jung M
J Med Chem; 2013 Sep; 56(18):7334-42. PubMed ID: 24007511
[TBL] [Abstract][Full Text] [Related]
8. Identifying the novel inhibitors of lysine-specific demethylase 1 (LSD1) combining pharmacophore-based and structure-based virtual screening.
Sun XD; Zheng YC; Ma CY; Yang J; Gao QB; Yan Y; Wang ZZ; Li W; Zhao W; Liu HM; Ding L
J Biomol Struct Dyn; 2019 Oct; 37(16):4200-4214. PubMed ID: 30366512
[TBL] [Abstract][Full Text] [Related]
9. Identification of Novel Selective Lysine-Specific Demethylase 1 (LSD1) Inhibitors Using a Pharmacophore-Based Virtual Screening Combined with Docking.
Zhou C; Kang D; Xu Y; Zhang L; Zha X
Chem Biol Drug Des; 2015 Jun; 85(6):659-71. PubMed ID: 25346381
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of novel (E)-N'-(2,3-dihydro-1H-inden-1-ylidene) benzohydrazides as potent LSD1 inhibitors.
Zhou Y; Li Y; Wang WJ; Xiang P; Luo XM; Yang L; Yang SY; Zhao YL
Bioorg Med Chem Lett; 2016 Sep; 26(18):4552-4557. PubMed ID: 27524309
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of tetrahydroquinoline-based reversible LSD1 inhibitors.
Wang X; Zhang C; Zhang X; Yan J; Wang J; Jiang Q; Zhao L; Zhao D; Cheng M
Eur J Med Chem; 2020 May; 194():112243. PubMed ID: 32229389
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis, and In Vitro Evaluation of Novel Histone H3 Peptide-Based LSD1 Inactivators Incorporating α,α-Disubstituted Amino Acids with γ-Turn-Inducing Structures.
Ota Y; Kakizawa T; Itoh Y; Suzuki T
Molecules; 2018 May; 23(5):. PubMed ID: 29734782
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of novel benzofuran derivatives as potent LSD1 inhibitors.
Zhang X; Huang H; Zhang Z; Yan J; Wu T; Yin W; Sun Y; Wang X; Gu Y; Zhao D; Cheng M
Eur J Med Chem; 2021 Aug; 220():113501. PubMed ID: 33945992
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological activity of 4-(4-benzyloxy)phenoxypiperidines as selective and reversible LSD1 inhibitors.
Xi J; Xu S; Zhang L; Bi X; Ren Y; Liu YC; Gu Y; Xu Y; Lan F; Zha X
Bioorg Chem; 2018 Aug; 78():7-16. PubMed ID: 29524666
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.
Ota Y; Miyamura S; Araki M; Itoh Y; Yasuda S; Masuda M; Taniguchi T; Sowa Y; Sakai T; Itami K; Yamaguchi J; Suzuki T
Bioorg Med Chem; 2018 Feb; 26(3):775-785. PubMed ID: 29331452
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors.
Nie Z; Shi L; Lai C; Severin C; Xu J; Del Rosario JR; Stansfield RK; Cho RW; Kanouni T; Veal JM; Stafford JA; Chen YK
Bioorg Med Chem Lett; 2019 Jan; 29(1):103-106. PubMed ID: 30409536
[TBL] [Abstract][Full Text] [Related]
17. Drug Design Concepts for LSD1-Selective Inhibitors.
Ota Y; Suzuki T
Chem Rec; 2018 Dec; 18(12):1782-1791. PubMed ID: 30277644
[TBL] [Abstract][Full Text] [Related]
18. 4-Hydroxy-3-methylbenzofuran-2-carbohydrazones as novel LSD1 inhibitors.
He X; Gao Y; Hui Z; Shen G; Wang S; Xie T; Ye XY
Bioorg Med Chem Lett; 2020 May; 30(10):127109. PubMed ID: 32201021
[TBL] [Abstract][Full Text] [Related]
19. Identification of cell-active lysine specific demethylase 1-selective inhibitors.
Ueda R; Suzuki T; Mino K; Tsumoto H; Nakagawa H; Hasegawa M; Sasaki R; Mizukami T; Miyata N
J Am Chem Soc; 2009 Dec; 131(48):17536-7. PubMed ID: 19950987
[TBL] [Abstract][Full Text] [Related]
20. Discovery and synthesis of novel indole derivatives-containing 3-methylenedihydrofuran-2(3H)-one as irreversible LSD1 inhibitors.
Liu HM; Suo FZ; Li XB; You YH; Lv CT; Zheng CX; Zhang GC; Liu YJ; Kang WT; Zheng YC; Xu HW
Eur J Med Chem; 2019 Aug; 175():357-372. PubMed ID: 31096156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]